Intra-articular injection of triamcinolone acetonide sustains macrophage levels and aggravates osteophytosis during degenerative joint disease in mice.
inflammation
macrophage
monocyte
osteoarthritis
osteophytes corticosteroid
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
03
11
2021
received:
05
08
2021
accepted:
27
11
2021
pubmed:
16
12
2021
medline:
7
5
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
Corticosteroids such as triamcinolone acetonide (TAA) are potent drugs administered intra-articularly as an anti-inflammatory therapy to relieve pain associated with osteoarthritis (OA). However, the ability of early TAA intervention to mitigate OA progression and modulate immune cell subsets remains unclear. Here, we sought to understand the effect of early intra-articular injection of TAA on OA progression, local macrophages, and peripheral blood monocytes. Degenerative joint disease was induced by intra-articular injection of collagenase into the knee joint of male C57BL/6 mice. After 1 week, TAA or saline was injected intra-articularly. Blood was taken throughout the study to analyse monocyte subsets. Mice were killed at days 14 and 56 post-induction of collagenase-induced OA (CiOA) to examine synovial macrophages and structural OA features. The percentage of macrophages relative to total live cells present within knee joints was increased in collagenase- compared with saline-injected knees at day 14 and was not altered by TAA treatment. However, at day 56, post-induction of CiOA, TAA-treated knees had increased levels of macrophages compared with the knees of untreated CiOA-mice. The distribution of monocyte subsets present in peripheral blood was not altered by TAA treatment during the development of CiOA. Osteophyte maturation was increased in TAA-injected knees at day 56. Intra-articular injection of TAA increases long-term synovial macrophage numbers and osteophytosis. Our findings suggest that TAA accentuates the progression of osteoarthritis-associated features when applied to an acutely inflamed knee.
Sections du résumé
BACKGROUND AND PURPOSE
Corticosteroids such as triamcinolone acetonide (TAA) are potent drugs administered intra-articularly as an anti-inflammatory therapy to relieve pain associated with osteoarthritis (OA). However, the ability of early TAA intervention to mitigate OA progression and modulate immune cell subsets remains unclear. Here, we sought to understand the effect of early intra-articular injection of TAA on OA progression, local macrophages, and peripheral blood monocytes.
EXPERIMENTAL APPROACH
Degenerative joint disease was induced by intra-articular injection of collagenase into the knee joint of male C57BL/6 mice. After 1 week, TAA or saline was injected intra-articularly. Blood was taken throughout the study to analyse monocyte subsets. Mice were killed at days 14 and 56 post-induction of collagenase-induced OA (CiOA) to examine synovial macrophages and structural OA features.
KEY RESULTS
The percentage of macrophages relative to total live cells present within knee joints was increased in collagenase- compared with saline-injected knees at day 14 and was not altered by TAA treatment. However, at day 56, post-induction of CiOA, TAA-treated knees had increased levels of macrophages compared with the knees of untreated CiOA-mice. The distribution of monocyte subsets present in peripheral blood was not altered by TAA treatment during the development of CiOA. Osteophyte maturation was increased in TAA-injected knees at day 56.
CONCLUSION AND IMPLICATIONS
Intra-articular injection of TAA increases long-term synovial macrophage numbers and osteophytosis. Our findings suggest that TAA accentuates the progression of osteoarthritis-associated features when applied to an acutely inflamed knee.
Identifiants
pubmed: 34907535
doi: 10.1111/bph.15780
pmc: PMC9305889
doi:
Substances chimiques
Collagenases
EC 3.4.24.-
Triamcinolone Acetonide
F446C597KA
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2771-2784Informations de copyright
© 2022 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Ann Rheum Dis. 2020 Dec;79(12):1625-1634
pubmed: 32963046
J Allergy Clin Immunol. 2020 Nov;146(5):1137-1151
pubmed: 32199911
Br J Pharmacol. 2020 Aug;177(16):3611-3616
pubmed: 32662875
Ann Rheum Dis. 2012 Sep;71(9):1552-8
pubmed: 22504564
Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S17-23
pubmed: 20864019
PLoS Biol. 2020 Jul 14;18(7):e3000410
pubmed: 32663219
Ann Rheum Dis. 2018 Jun;77(6):875-882
pubmed: 29514801
Front Immunol. 2019 May 24;10:1084
pubmed: 31178859
Osteoarthritis Cartilage. 2020 May;28(5):555-561
pubmed: 31982565
Osteoarthritis Cartilage. 2014 Mar;22(3):363-88
pubmed: 24462672
J Immunol. 2014 Aug 1;193(3):1090-9
pubmed: 24990080
J Biol Chem. 1985 Jan 10;260(1):160-4
pubmed: 3965445
Ann Rheum Dis. 2018 Oct;77(10):1490-1497
pubmed: 29959183
Int J Obes (Lond). 2007 Sep;31(9):1420-8
pubmed: 17593905
BMC Musculoskelet Disord. 2020 Apr 11;21(1):225
pubmed: 32278346
Cell Rep. 2014 Oct 23;9(2):591-604
pubmed: 25373902
Osteoarthritis Cartilage. 2002 Aug;10(8):611-6
pubmed: 12479382
J Immunol. 2015 Jun 1;194(11):5150-60
pubmed: 25911752
Steroids. 2013 Jan;78(1):59-68
pubmed: 23127816
Osteoarthritis Cartilage. 2018 Jan;26(1):34-42
pubmed: 29024802
Br J Pharmacol. 2019 Oct;176(20):4050-4064
pubmed: 31378925
Front Immunol. 2019 Oct 17;10:2460
pubmed: 31681333
Arthritis Care Res (Hoboken). 2020 Feb;72(2):149-162
pubmed: 31908149
Biochim Biophys Acta. 2013 Jul;1832(7):989-97
pubmed: 23246690
Osteoarthritis Cartilage. 2016 Jul;24(7):1143-52
pubmed: 26836288
Cartilage. 2021 Dec;13(2_suppl):168S-174S
pubmed: 34165367
Am J Sports Med. 2018 Mar;46(4):977-986
pubmed: 29373806
Rheumatol Int. 1996;16(3):115-9
pubmed: 8893376
Arthritis Rheum. 2011 Sep;63(9):2690-9
pubmed: 21360519
Nat Rev Rheumatol. 2016 Oct;12(10):580-92
pubmed: 27539668
J Bone Joint Surg Br. 1958 Nov;40-B(4):636-43
pubmed: 13610976
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Gene. 2016 Oct 10;591(1):1-5
pubmed: 27356303
Immunity. 2003 Jul;19(1):71-82
pubmed: 12871640
Nat Rev Endocrinol. 2020 Aug;16(8):437-447
pubmed: 32286516
Drugs. 2019 Mar;79(4):455-462
pubmed: 30847805
Ann Rheum Dis. 1998 Dec;57(12):732-7
pubmed: 10070273
Osteoarthritis Cartilage. 2007 Mar;15(3):237-44
pubmed: 17204437
J Leukoc Biol. 2000 Jan;67(1):97-103
pubmed: 10648003
Arthritis Res Ther. 2015 Dec 05;17:352
pubmed: 26637220
J Immunol. 2004 Apr 1;172(7):4410-7
pubmed: 15034056
Cochrane Database Syst Rev. 2015 Oct 22;(10):CD005328
pubmed: 26490760
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1673-9
pubmed: 24782446
J Immunol Methods. 1998 Aug 1;217(1-2):27-39
pubmed: 9776572
Cell Immunol. 2014 May-Jun;289(1-2):135-9
pubmed: 24791698
Radiology. 2019 Dec;293(3):656-663
pubmed: 31617798
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Knee. 2016 Dec;23(6):1148-1153
pubmed: 27856128
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005328
pubmed: 16625636
Ann Rheum Dis. 2001 Jan;60(1):6
pubmed: 11114274
Blood. 2007 Feb 1;109(3):1265-74
pubmed: 17018861
Br J Pharmacol. 2022 Jun;179(11):2771-2784
pubmed: 34907535
Br J Pharmacol. 2021 Oct;178 Suppl 1:S1-S26
pubmed: 34529830
J Leukoc Biol. 2008 Sep;84(3):644-50
pubmed: 18611985
Am J Sports Med. 2017 Feb;45(2):325-333
pubmed: 28146402
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Osteoarthritis Cartilage. 2004 Aug;12(8):627-35
pubmed: 15262242
J Leukoc Biol. 2003 Jul;74(1):33-9
pubmed: 12832440
Osteoarthritis Cartilage. 2019 Jun;27(6):855-862
pubmed: 30703543
J Rheumatol. 1996 Jul;23(7):1227-32
pubmed: 8823697
Am J Respir Cell Mol Biol. 2012 Oct;47(4):417-26
pubmed: 22721830
JAMA. 2017 May 16;317(19):1967-1975
pubmed: 28510679
Arthritis Rheum. 2004 Jan;50(1):103-11
pubmed: 14730606